Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.63 USD +7.47% Intraday chart for Moleculin Biotech, Inc. -0.43% -64.04%
Apr. 18 Sector Update: Health Care Stocks Ease in Afternoon Trading MT
Apr. 18 Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU MT

Evolution of the average Target Price on Moleculin Biotech, Inc.

Price target over the last 5 years

History of analyst recommendation changes

2fe1c988ebfc1a3b2c2c31164889f58.nrSNHS-d9AP1lA48QQ6L3FfdBNO1ilcJ1ThWdPQeUdY.p43KLB7PrWGh4ltvNl_vrB2nbrHQyAZR7HllBLJNP7nUxd1XXPbNYLHyVw~94982c6e3d07ce2a3448e1b6cab23d73

Analyst Recommendations on Moleculin Biotech, Inc.

Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating MT
HC Wainwright Initiates Moleculin Biotech With Buy Rating, Price Target is $3 MT
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months CI
Roth Capital Adjusts Moleculin Biotech's Price Target to $16 From $29, Reiterates Buy Rating MT
MOLECULIN BIOTECH : Oppenheimer Adjusts Moleculin Biotech's Price Target to $18 From Post-Split Adjusted $12, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.63 USD
Average target price
35 USD
Spread / Average Target
+655.94%
High Price Target
45 USD
Spread / Highest target
+871.92%
Low Price Target
20 USD
Spread / Lowest Target
+331.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Moleculin Biotech, Inc.

Maxim
HC Wainwright
Roth Capital Partners
Oppenheimer

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. Consensus Moleculin Biotech, Inc.